13 Jul 2020 14:23
Polarean Imaging Plc
("Polarean" or the "Company")
Result of AGM
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that at the AGM held earlier today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:
Resolution | For | Against |
Resolution 1 | 69,040,651 | 0 |
Resolution 2 | 69,035,550 | 5,101 |
Resolution 3 | 69,040,651 | 0 |
Resolution 4 | 69,040,651 | 0 |
Resolution 5 | 69,040,651 | 0 |
Resolution 6 | 69,040,651 | 0 |
Resolution 7 | 69,010,651 | 0 |
Resolution 8 | 68,885,651 | 125,000 |
Contacts:
Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | |||
Richard Hullihen, Chief Executive Officer Jonathan Allis, Chairman | Via Walbrook PR
| |||
SP Angel Corporate Finance LLP Nomad and Broker | Tel: +44 (0)20 3470 0470 | |||
David Hignell / Soltan Tagiev (Corporate Finance) | ||||
Vadim Alexandre / Rob Rees (Corporate Broking) | ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | |||
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001 | |||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimize the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.
polarean (POLX)